Current Hypertension Reports

, Volume 12, Issue 6, pp 456–464 | Cite as

Genetic Testing for Pheochromocytoma

Article

Abstract

Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are rare, catecholamine-producing tumors that are usually sporadic. However, about 30% of these tumors have been identified as being of inherited origin. To date, nine genes have been confirmed as participating in PHEO or PGL tumorigenesis. Germline mutations were found in 100% of syndromic cases and in about 90% of patients with positive familial history. In nonsyndromic patients with apparently sporadic tumors, genetic mutations have been found in up to 27%, and genetic testing is now recommended for all patients with PHEOs and PGLs. Patients with syndromic lesions, a positive family history, or both should be tested for the appertaining gene. Recent discoveries have shown that the order of tested genes in nonsyndromic, nonfamilial cases can be based on histologic evaluation, location, and the biochemical phenotype of PHEOs and PGLs—the “rule of three.” Identification of a gene mutation may lead to early diagnosis and treatment, regular surveillance, and a better prognosis for patients and their relatives.

Keywords

Genetic testing Paraganglioma Pheochromocytoma Multiple endocrine neoplasia type 2 von Hippel-Lindau disease Neurofibromatosis type 1 Succinate dehydrogenase complex genes Immunohistochemistry Catecholamines 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Koch CA, Vortmeyer AO, Huang SC, et al.: Genetic aspects of pheochromocytoma. Endocr Regul 2001, 35:43–52. Erratum in: Endocr Regul 2001, 35:94.Google Scholar
  2. 2.
    Bryant J, Farmer J, Kessler LJ, et al.: Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst 2003, 95:1196–1204.CrossRefPubMedGoogle Scholar
  3. 3.
    Benn DE, Robinson BG: Genetic basis of phaeochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab 2006, 20:435–450.CrossRefPubMedGoogle Scholar
  4. 4.
    •• Burnichon N, Brière JJ, Libé R, et al.: SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 2010, 19:3011–3020. These authors identified a heterozygous germline SDHA mutation, p.Arg589Trp, in a woman suffering from catecholamine-secreting abdominal PGL. They also investigated 202 PHEOs and PGLs for loss of heterozygosity (LOH) at the SDHA, SDHB, SDHC, and SDHD loci. LOH was detected at the SDHA locus in the patient’s tumor but was present in only 4.5% of a large series of PHEOs and PGLs. CrossRefPubMedGoogle Scholar
  5. 5.
    •• Hao HX, Khalimonchuk O, Schraders M, et al.: SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 2009, 325:1139–1142. These authors investigated a mitochondrial protein named SDH5, which interacts with the catalytic subunit of the SDH complex. SDH5 is required for SDH-dependent respiration and for SDHA flavination (incorporation of the flavin adenine dinucleotide cofactor). Germline loss-of-function mutations in the human SDH5 gene, located on chromosome 11q13.1, segregate with disease in a family with hereditary PGLs. CrossRefPubMedGoogle Scholar
  6. 6.
    •• Bayley JP, Kunst HP, Cascon A, et al.: SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol 2010, 11:366–372. These authors identified a pathogenic germline DNA mutation of SDHAF2, 232G-- > A (Gly78Arg) in a family with head and neck PGLs with a young age of onset. CrossRefPubMedGoogle Scholar
  7. 7.
    •• Qin Y, Yao L, King EE, et al.: Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet 2010, 42:229–233. These authors identified the transmembrane-encoding gene, TMEM127 on chromosome 2q11, as a new PHEO susceptibility gene. In a cohort of 103 samples, they detected truncating germline TMEM127 mutations in approximately 30% of familial tumors and about 3% of sporadic-appearing PHEOs. CrossRefPubMedGoogle Scholar
  8. 8.
    Neumann HP, Bausch B, McWhinney SR, et al.: Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002, 346:1459-1466.CrossRefPubMedGoogle Scholar
  9. 9.
    •• Mannelli M, Castellano M, Schiavi F, et al.: Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab 2009, 94:1541–1547. These authors examined 501 consecutive patients with PHEOs or PGLs (secreting or nonsecreting). Germline mutations were detected in 32.1% of cases, but frequencies varied widely depending on the classification criteria, ranging from 100% in patients with associated syndromic lesions to 11.6% in patients with a single tumor and a negative family history. CrossRefPubMedGoogle Scholar
  10. 10.
    Amar L, Bertherat J, Baudin E, et al.: Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 2005, 23:8812–8818.CrossRefPubMedGoogle Scholar
  11. 11.
    •• Burnichon N, Rohmer V, Amar L, et al.: The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab 2009, 94:2817–2827. These authors examined 445 patients with head-and-neck and/or thoracic-abdominal or pelvic PGLs. A head-and-neck PGL was present in 97.7% of carriers of an SDHD mutation and 87.5% of SDHC mutation carriers, but in only 42.7% of SDHB carriers; on the other hand, a thoracic-abdominal or pelvic location was present in 63.5% of carriers of an SDHB mutation, 16.1% of SDHD mutation carriers, and 12.5% of those with an SDHC mutation. A malignant PGL was documented in 37.5% of the SDHB mutation carriers versus 3.1% with an SDHD mutation and none with an SDHC mutation. CrossRefPubMedGoogle Scholar
  12. 12.
    •• Timmers HJ, Kozupa A, Eisenhofer G, et al.: Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 2007, 92:779–786. This study included 29 patients with SDHB-related abdominal or thoracic PGLs. The mean age at diagnosis was 33.7 ± 15.7 years. Tumor-related pain was among the presenting symptoms in 54% of patients. Hypertension was present in 76%, and 90% lacked a family history of PGL. All primary tumors but one originated from extra-adrenal locations. The mean tumor size (± SD) was 7.8 ± 3.7 cm. Twenty-eight percent of patients presented with metastatic disease, and all but one eventually developed metastases after 2.7 ± 4.1 years. The biochemical phenotype was consistent with hypersecretion of both norepinephrine and dopamine in 46%, norepinephrine only in 41%, and dopamine only in 3%. No obvious genotype-phenotype correlations were identified. CrossRefPubMedGoogle Scholar
  13. 13.
    •• Amar L, Baudin E, Burnichon N, et al.: Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 2007, 10:3822–3828. This study included 54 patients with malignant PHEOs/PGLs. Germline mutations were identified in SDHB genes (n = 23, including 21 patients with apparent sporadic tumors) and VHL genes (n = 1); two patients had NF1. Patients with SDHB mutations were younger, more frequently had extra-adrenal tumors, and had a shorter metanephrine excretion doubling time. The presence of SDHB mutations was significantly and independently associated with mortality. Google Scholar
  14. 14.
    Raue F, Frank-Raue K: Multiple endocrine neoplasia type 2: 2007 update. Horm Res 2007, 68(Suppl 5):101–104.CrossRefPubMedGoogle Scholar
  15. 15.
    Pacak K, Eisenhofer G, Ilias I: Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. Hormones (Athens) 2009, 8:111–116.Google Scholar
  16. 16.
    Mulligan LM, Marsh DJ, Robinson BG, et al.: Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 1995, 238:343–346.CrossRefPubMedGoogle Scholar
  17. 17.
    Lenders JW, Eisenhofer G, Mannelli M, Pacak K: Phaeochromocytoma. Lancet 2005, 366:665–675.CrossRefPubMedGoogle Scholar
  18. 18.
    Eisenhofer G, Walther MM, Huynh TT, et al.: Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 2001, 86:1999–2008.CrossRefPubMedGoogle Scholar
  19. 19.
    Maher ER, Yates JR, Harries R, et al.: Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990, 77:1151–1163.PubMedGoogle Scholar
  20. 20.
    Elder EE, Elder G, Larsson C: Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor. J Surg Oncol 2005, 89:193–201.CrossRefPubMedGoogle Scholar
  21. 21.
    Petri BJ, van Eijck CH, de Herder WW, et al.: Phaeochromocytomas and sympathetic paragangliomas. Br J Surg 2009, 96:1381–1392.CrossRefPubMedGoogle Scholar
  22. 22.
    Maxwell PH, Wiesener MS, Chang GW, et al.: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271–275.CrossRefPubMedGoogle Scholar
  23. 23.
    Hes FJ, Höppener JW, Lips CJ: Clinical review 155: Pheochromocytoma in Von Hippel-Lindau disease. J Clin Endocrinol Metab 2003, 88:969–974.CrossRefPubMedGoogle Scholar
  24. 24.
    •• Srirangalingam U, Khoo B, Walker L, et al.: Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours. Endocr Relat Cancer 2009, 16:515–525. This study assessed 31 patients with chromaffin tumors; 16 had SDHB gene mutations and 15 had a diagnosis of VHL. VHL-related tumors were predominantly adrenal PHEOs (84.6%), whereas SDHB-related tumors were predominantly extra-adrenal PGLs (76%). Multifocal disease (bilateral PHEOs) was present in 60% of the VHL cohort but only 19% of the SDHB cohort, whereas metastatic disease was found in 31% of the SDHB cohort but was not found in the VHL cohort. CrossRefPubMedGoogle Scholar
  25. 25.
    • Boedeker CC, Erlic Z, Richard S, et al.: Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 2009, 94:1938–1944. From a total of 809 head and neck PGLs, 12 patients were found to have hereditary non-SDHx head-and-neck PGLs: 11 in the setting of germline VHL mutations and one with a RET mutation. CrossRefPubMedGoogle Scholar
  26. 26.
    Walther MM, Herring J, Enquist E, et al.: von Recklinghausen’s disease and pheochromocytomas. J Urol 1999, 162:1582–1586.CrossRefPubMedGoogle Scholar
  27. 27.
    Zöller ME, Rembeck B, Odén A, et al.: Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 1997, 79:2125–2131.CrossRefPubMedGoogle Scholar
  28. 28.
    Gutmann DH, Aylsworth A, Carey JC, et al.: The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997, 278:51–57.CrossRefPubMedGoogle Scholar
  29. 29.
    Bausch B, Borozdin W, Neumann HP; European-American Pheochromocytoma Study Group: Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N Engl J Med 2006, 354:2729–2731.CrossRefPubMedGoogle Scholar
  30. 30.
    Astuti D, Latif F, Dallol A, et al.: Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001, 69:49–54. Erratum in Am J Hum Genet 2002, 70:565.Google Scholar
  31. 31.
    Niemann S, Müller U: Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000, 26:268–270.CrossRefPubMedGoogle Scholar
  32. 32.
    Baysal BE, Ferrell RE, Willett-Brozick JE, et al.: Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000, 287:848–851.CrossRefPubMedGoogle Scholar
  33. 33.
    Timmers HJ, Gimenez-Roqueplo AP, Mannelli M, Pacak K: Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer 2009, 16:391–400.CrossRefPubMedGoogle Scholar
  34. 34.
    Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029–1033.Google Scholar
  35. 35.
    Hensen EF, Jordanova ES, van Minderhout IJ, et al.: Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene 2004, 23:4076–4083.CrossRefPubMedGoogle Scholar
  36. 36.
    Jiménez C, Cote G, Arnold A, Gagel RF: Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab 2006, 91:2851–2858.CrossRefPubMedGoogle Scholar
  37. 37.
    • Peczkowska M, Cascon A, Prejbisz A, et al.: Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation. Nat Clin Pract Endocrinol Metab 2008, 4:111–115. The family presented had adrenal pheochromocytoma and carotid body tumor as parts of a familial PHEO-PGL syndrome associated with a germline mutation in the SDHC gene. CrossRefPubMedGoogle Scholar
  38. 38.
    • Ricketts C, Woodward ER, Killick P, et al.: Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst 2008, 100:1260–1262. These authors investigated whether germline mutations in SDH subunit genes (SDHB, SDHC, SDHD) were associated with renal cell carcinoma (RCC) susceptibility in 68 patients with no clinical evidence of an RCC susceptibility syndrome. No mutations in SDHC or SDHD were identified in probands, but 3 (4.4%) of the 68 probands had a germline SDHB mutation. CrossRefPubMedGoogle Scholar
  39. 39.
    • Pasini B, McWhinney SR, Bei T, et al.: Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 2008, 16:79–88. These authors investigated 11 patients with the dyad of PGL and gastric stromal sarcoma; in 8, the GISTs were caused by germline mutations of SDHB, SDHC, or SDHD genes. CrossRefPubMedGoogle Scholar
  40. 40.
    Lee J, Wang J, Torbenson M, et al.: Loss of SDHB and NF1 genes in a malignant phyllodes tumor of the breast as detected by oligo-array comparative genomic hybridization. Cancer Genet Cytogenet 2010, 196:179–183.CrossRefPubMedGoogle Scholar
  41. 41.
    Neumann HP, Pawlu C, Peczkowska M, et al.: Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004, 292:943–951. Erratum in: JAMA 2004, 292:1686.Google Scholar
  42. 42.
    Brouwers FM, Eisenhofer G, Tao JJ, et al.: High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab 2006, 91:4505–4509.CrossRefPubMedGoogle Scholar
  43. 43.
    Benn DE, Gimenez-Roqueplo AP, Reilly JR, et al.: Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 2006, 91:827–836.CrossRefPubMedGoogle Scholar
  44. 44.
    •• Ricketts CJ, Forman JR, Rattenberry E, et al.: Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat 2010, 31:41–51. Authors assessed 358 patients with SDHB (n = 295) and SDHD (n = 63) mutations. At age 60 years, the risk of head and neck PGL in SDHB mutation carriers was 29% and the risk of PHEO was 52%; in SDHD mutation carriers, the risks were and 71% and 29%, respectively. Risks of malignant PHEO and renal tumors (14% at age 70 years) were higher in SDHB mutation carriers. No clear genotype-phenotype correlations were detected for SDHB mutations. CrossRefPubMedGoogle Scholar
  45. 45.
    •• Gill AJ, Benn DE, Chou A, et al.: Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol 2010, 41:805–814. These authors defined positive, weak diffuse, and negative immunohistochemistry staining for SDHB. All 12 SDH mutated tumors (6 SDHB, 5 SDHD, and 1 SDHC) showed weak diffuse or negative staining, whereas 9 of 10 tumors with known mutations of VHL, RET, or NF1 showed positive staining. One VHL-associated tumor showed weak diffuse staining; one PGL with no known SDH mutation but clinical features suggesting familial disease was negative, and one showed weak diffuse staining. Completely absent staining is more commonly found with SDHB mutation, whereas weak diffuse staining often occurs with SDHD mutation. CrossRefPubMedGoogle Scholar
  46. 46.
    •• van Nederveen FH, Gaal J, Favier J, et al.: An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 2009, 10:764–771. Immunohistochemistry for SDHB was done on 220 tumors. SDHB protein expression was absent in all 102 PHEOs and PGLs with an SDHB, SDHC, or SDHD mutation, but was present in all 65 tumors related to MEN 2, VHL, and NF1. Of the 53 PHEOs or PGLs with no syndromic germline mutation, 47 (89%) showed SDHB expression. The SDHB immunohistochemistry was 100% sensitive (95% CI, 87%–100%) in detecting the presence of an SDH mutation in the prospective series, and 84% specific (95% CI, 60%–97%). CrossRefPubMedGoogle Scholar
  47. 47.
    •• Cascón A, Pita G, Burnichon N, et al.: Genetics of pheochromocytoma and paraganglioma in Spanish patients. J Clin Endocrinol Metab 2009, 94:1701–1705. This study analyzed 237 nonrelated probands for the major susceptibility genes: VHL, RET, SDHB, SDHC, and SDHD. All syndromic probands were genetically diagnosed with a mutation affecting either RET or VHL. A total of 79.1% of patients presenting with nonsyndromic familial antecedents and 18.4% of those with apparently sporadic presentation were found to carry a mutation in one of the susceptibility genes. CrossRefPubMedGoogle Scholar
  48. 48.
    •• Erlic Z, Rybicki L, Peczkowska M, et al.: Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clin Cancer Res 2009, 15:6378–6385. Of 989 apparently nonsyndromic PHEOs, 187 (19%) harbored germline mutations. Predictors for the presence of mutation were estimated: age less than 45 years, multiple PHEOs, extra-adrenal location, and previous head-and-neck PGL. CrossRefPubMedGoogle Scholar
  49. 49.
    Pacak K, Eisenhofer G, Ahlman H, et al.; International Symposium on Pheochromocytoma: Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 2007, 3:92–102.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC (outside the USA)  2010

Authors and Affiliations

  1. 1.Reproductive and Adult Endocrinology Program, NICHD, NIHBethesdaUSA
  2. 2.3rd Department of Internal MedicineUniversity Hospital OlomoucOlomoucCzech Republic

Personalised recommendations